These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 37230295)

  • 41. Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors.
    Qiao J; Wang H; Kottke T; Diaz RM; Willmon C; Hudacek A; Thompson J; Parato K; Bell J; Naik J; Chester J; Selby P; Harrington K; Melcher A; Vile RG
    Gene Ther; 2008 Apr; 15(8):604-16. PubMed ID: 18305577
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Quercetin-ferrum nanoparticles enhance photothermal therapy by modulating the tumor immunosuppressive microenvironment.
    Li L; Zhang M; Liu T; Li J; Sun S; Chen J; Liu Z; Zhang Z; Zhang L
    Acta Biomater; 2022 Dec; 154():454-466. PubMed ID: 36243377
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combined dendritic cell cryotherapy of tumor induces systemic antimetastatic immunity.
    Machlenkin A; Goldberger O; Tirosh B; Paz A; Volovitz I; Bar-Haim E; Lee SH; Vadai E; Tzehoval E; Eisenbach L
    Clin Cancer Res; 2005 Jul; 11(13):4955-61. PubMed ID: 16000595
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS.
    de Goeje PL; Klaver Y; Kaijen-Lambers MEH; Langerak AW; Vroman H; Kunert A; Lamers CHJ; Aerts JGJV; Debets R; Hendriks RW
    Front Immunol; 2018; 9():2034. PubMed ID: 30245692
    [No Abstract]   [Full Text] [Related]  

  • 45. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
    Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
    J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance.
    Bonifaz L; Bonnyay D; Mahnke K; Rivera M; Nussenzweig MC; Steinman RM
    J Exp Med; 2002 Dec; 196(12):1627-38. PubMed ID: 12486105
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adenovirus-mediated expression of interleukin-12 induces natural killer cell activity and complements adenovirus-directed gp75 treatment of melanoma lung metastases.
    Hirschowitz EA; Crystal RG
    Am J Respir Cell Mol Biol; 1999 May; 20(5):935-41. PubMed ID: 10226063
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Study on the specific immunity induced by dendritic cell vaccine loading allogenic microvascular endothelial cell bEnd.3 antigen against U14 cervical cancer cell in mice].
    Zhao J; Lu J; Liu YQ; Yang HY; Huang YT; Zhao JM; Li S; Zhai JM; Zhao MY; Zhang X; Dong ZM
    Zhonghua Fu Chan Ke Za Zhi; 2011 Jan; 46(1):52-7. PubMed ID: 21429436
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
    Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
    J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment.
    Yang M; Li J; Gu P; Fan X
    Bioact Mater; 2021 Jul; 6(7):1973-1987. PubMed ID: 33426371
    [TBL] [Abstract][Full Text] [Related]  

  • 51. "Cytokine-microfactories" recruit DCs and deliver tumor antigens via gap junctions for immunotherapy.
    Guo L; Wei RX; Sun R; Yang Q; Li GJ; Wang LY; Luo HB; Feng M
    J Control Release; 2021 Sep; 337():417-430. PubMed ID: 34324896
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Persistent, antigen-specific, therapeutic antitumor immunity by dendritic cells genetically modified with an adenoviral vector to express a model tumor antigen.
    Song W; Tong Y; Carpenter H; Kong HL; Crystal RG
    Gene Ther; 2000 Dec; 7(24):2080-6. PubMed ID: 11223988
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
    Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G
    Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives.
    Morisaki T; Matsumoto K; Onishi H; Kuroki H; Baba E; Tasaki A; Kubo M; Nakamura M; Inaba S; Yamaguchi K; Tanaka M; Katano M
    Hum Cell; 2003 Dec; 16(4):175-82. PubMed ID: 15147037
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Programmed Catalytic Therapy-Mediated ROS Generation and T-Cell Infiltration in Lung Metastasis by a Dual Metal-Organic Framework (MOF) Nanoagent.
    Nirosha Yalamandala B; Chen PH; Moorthy T; Huynh TMH; Chiang WH; Hu SH
    Pharmaceutics; 2022 Feb; 14(3):. PubMed ID: 35335903
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Engineered red blood cells (activating antigen carriers) drive potent T cell responses and tumor regression in mice.
    Blagovic K; Smith CK; Ramakrishnan A; Moore L; Soto DR; Thompson Z; Stockmann AP; Kruszelnicki S; Thakkar A; Murray J; Torres S; Wondimagegnhu B; Yi R; Dadgar M; Paracha AM; Page C; Clear L; Chaudhry OA; Myint M; Bridgen DT; Gilbert JB; Seidl KJ; Sharei A; Loughhead S; Bernstein H; Yarar D
    Front Immunol; 2022; 13():1015585. PubMed ID: 36263022
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies.
    Hägerbrand K; Varas L; Deronic A; Nyesiga B; Sundstedt A; Ljung L; Sakellariou C; Werchau D; Thagesson M; Gomez Jimenez D; Greiff L; Celander M; Smedenfors K; Rosén A; Bölükbas D; Carlsson F; Levin M; Säll A; von Schantz L; Lindstedt M; Ellmark P
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36323431
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sustained and NK/CD4+ T cell-dependent efficient prevention of lung metastasis induced by dendritic cells harboring recombinant Sendai virus.
    Komaru A; Ueda Y; Furuya A; Tanaka S; Yoshida K; Kato T; Kinoh H; Harada Y; Suzuki H; Inoue M; Hasegawa M; Ichikawa T; Yonemitsu Y
    J Immunol; 2009 Oct; 183(7):4211-9. PubMed ID: 19734206
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Determinant roles of dendritic cell-expressed Notch Delta-like and Jagged ligands on anti-tumor T cell immunity.
    Tchekneva EE; Goruganthu MUL; Uzhachenko RV; Thomas PL; Antonucci A; Chekneva I; Koenig M; Piao L; Akhter A; de Aquino MTP; Ranganathan P; Long N; Magliery T; Valujskikh A; Evans JV; Arasada RR; Massion PP; Carbone DP; Shanker A; Dikov MM
    J Immunother Cancer; 2019 Apr; 7(1):95. PubMed ID: 30940183
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adoptively transferred human lung tumor specific cytotoxic T cells can control autologous tumor growth and shape tumor phenotype in a SCID mouse xenograft model.
    Oflazoglu E; Elliott M; Takita H; Ferrone S; Henderson RA; Repasky EA
    J Transl Med; 2007 Jun; 5():29. PubMed ID: 17592641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.